Crohn’s Disease - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Crohn’s Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Crohn’s Disease: Overview
Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn’s disease has the potential to progress extensively.
The disease can be witnessed in any age group; however, it is seen to be developing mostly in between 20 and 30 years of age. About one-sixth of patients present before the age of 15 and often with severe disease. The exact pathogenesis of CD is unknown, although there are a number of genetic and environmental factors that have been shown to increase the risk of the disease and lead to the aberrant gut immune response characteristic of the disease.
Crohn’s is a chronic illness that requires expensive medications, often hospitalization and/or surgery, and results in a heavy social and economic toll. Based on its phenotypic progression, Crohn’s can be characterized as inflammatory, fibrostenotic, or fistulizing, and may progress to extraintestinal or systemic manifestations. The broad clinical spectrum of the disease portends a diagnostic challenge, and requires a multi-disciplinary approach to provide the appropriate management. Various treatments and therapies are available that help in order to ease away the symptoms related to Crohn’s disease. Treatment of Crohn’s disease is guided by severity, behavior, and disease location, along with anatomic site, appearance of complications, treatment refractoriness and dependency to steroids.
Report Highlights
This segment of the Crohn’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Crohn’s Disease Emerging Drugs
In December 2020 Gilead and Galapagos announced new commercialization and development agreement for Jyseleca (Filgotinib). The announcement followed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for filgotinib in the treatment of RA. It is currently in Phase III stage of development for Crohn’s Disease.
In November 2016, Abbvie receives Orphan Drug Designation for investigational IL-23 inhibitor risankizumab from the U.S. Food and Drug Administration for the treatment of pediatric patients with crohn's disease.
Further product details are provided in the repor
Crohn’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Crohn’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
Crohn’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Crohn’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Crohn’s Disease drugs.
Crohn’s Disease Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Crohn’s Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Crohn’s Disease: Overview
Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn’s disease has the potential to progress extensively.
The disease can be witnessed in any age group; however, it is seen to be developing mostly in between 20 and 30 years of age. About one-sixth of patients present before the age of 15 and often with severe disease. The exact pathogenesis of CD is unknown, although there are a number of genetic and environmental factors that have been shown to increase the risk of the disease and lead to the aberrant gut immune response characteristic of the disease.
Crohn’s is a chronic illness that requires expensive medications, often hospitalization and/or surgery, and results in a heavy social and economic toll. Based on its phenotypic progression, Crohn’s can be characterized as inflammatory, fibrostenotic, or fistulizing, and may progress to extraintestinal or systemic manifestations. The broad clinical spectrum of the disease portends a diagnostic challenge, and requires a multi-disciplinary approach to provide the appropriate management. Various treatments and therapies are available that help in order to ease away the symptoms related to Crohn’s disease. Treatment of Crohn’s disease is guided by severity, behavior, and disease location, along with anatomic site, appearance of complications, treatment refractoriness and dependency to steroids.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Crohn’s Disease R&D. The therapies under development are focused on novel approaches for Crohn’s Disease.
This segment of the Crohn’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Crohn’s Disease Emerging Drugs
- Filgotinib: Gilead Sciences
In December 2020 Gilead and Galapagos announced new commercialization and development agreement for Jyseleca (Filgotinib). The announcement followed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for filgotinib in the treatment of RA. It is currently in Phase III stage of development for Crohn’s Disease.
- Risankizumab: Abbvie
In November 2016, Abbvie receives Orphan Drug Designation for investigational IL-23 inhibitor risankizumab from the U.S. Food and Drug Administration for the treatment of pediatric patients with crohn's disease.
Further product details are provided in the repor
Crohn’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Crohn’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Crohn’s Disease
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Crohn’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Crohn’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Crohn’s Disease drugs.
Crohn’s Disease Report Insights
- Crohn’s Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Crohn’s Disease drugs?
- How many Crohn’s Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Crohn’s Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Crohn’s Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Crohn’s Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Gilead Sciences
- Abbvie
- Eli Lilly and Company
- Celgene
- AstraZeneca
- Mesoblast
- Alfasigma
- Tiziana Life Sciences
- Pfizer
- Dermavant Sciences GmbH
- Cytocom
- Amgen
- Priothera
- SLA Pharma
- HAV Vaccines Ltd
- Enzo Biochem
- VHsquared Ltd.
- Stero Biotechs
- Reistone Biopharma Company Limited
- Qu Biologics
- Provention Bio
- Mitsubishi Tanabe Pharma Corporation
- Takeda Pharmaceuticals
- Soligenix
- Immunic
- Atlantic Healthcare
- 4D Pharma
- Landos Biopharma
- Janssen
- Protagonist Therapeutics
- Roche
- Eisai
- Bristol-Myers Squibb
- Iltoo Pharma
- Fast Forward Pharmaceuticals
- Suzhou Connect Biopharmaceuticals
- Theravance Biopharma
- TaiwanJ Pharmaceuticals
- Active Biotech
- Celularity
- Alpha Cancer Technologies
- Koutif Therapeutics
- Winston Pharmaceuticals
- Tract Therapeutics
- Trio medicines
- Tetherex Pharmaceuticals
- ChemoCentryx
- Algernon Pharmaceuticals
- Neuclone
- Filgotinib
- Risankizumab
- Mirikizumab
- Ozanimod
- Brazikumab
- Risankizumab
- Upadacitinib
- Remestemcel-L
- Rifaximin
- Foralumab
- ABX464
- Etrasimod
- CYTO-201
- Masitinib
- Mocravimod
- Ortem Topical metronidazole
- HAV anti-MAP vaccine
- Alequel
- V565
- Cannabidiol
- SHR0302
- QBECO-SSI
- PRV-6527
- PF-06651600
- MT-1303
- TAK-018
- SGX203
- IMU 838
- Brepocitinib
- Alicaforsen
- Bacteroides thetaiotaomicron
- BT-11
- JNJ-64304500
- PTG-200
- RG-7880
- E6011
- BMS-986165
- Spesolimab
- Aldesleukin
- FFP104
- CBP-307
- TD-1473
- JKB-122
- Laquinimod
- PDA-001
- IMU-856
- ACT-101
- KT-1002
- Civamide
- TregCel
- TR8
- SelK2
- CCX507
- NP-178
- NeuLara
Introduction
Executive Summary
Crohn’s Disease: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Crohn’s Disease– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Crohn’s Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Crohn’s Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Risankizumab: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Omilancor: Landos Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TregCel: Tract Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
OTL104: Orchard Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Crohn’s Disease Key Companies
Crohn’s Disease Key Products
Crohn’s Disease- Unmet Needs
Crohn’s Disease- Market Drivers and Barriers
Crohn’s Disease- Future Perspectives and Conclusion
Crohn’s Disease Analyst Views
Crohn’s Disease Key Companies
Appendix
Executive Summary
Crohn’s Disease: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Crohn’s Disease– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Crohn’s Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Crohn’s Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Risankizumab: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Omilancor: Landos Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TregCel: Tract Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
OTL104: Orchard Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Crohn’s Disease Key Companies
Crohn’s Disease Key Products
Crohn’s Disease- Unmet Needs
Crohn’s Disease- Market Drivers and Barriers
Crohn’s Disease- Future Perspectives and Conclusion
Crohn’s Disease Analyst Views
Crohn’s Disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Crohn’s Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Crohn’s Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Crohn’s Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Crohn’s Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
